Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Denosumab and teriparatide after single-level lumbar fusion in postmenopausal osteoporosis
ChiCTR2300076108Phase 4Recruiting
- Sponsor
- Dujiangyan People's Hospital
- Start
- Oct 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of denosumab and teriparatide in involutional osteoporosis (4 arms), sponsored by Dujiangyan People's Hospital. Primary endpoint: Fusion rate. Started Oct 2023; status: recruiting.
02
Drugs
denosumabteriparatide
03
Conditions
involutional osteoporosis
Beyond the preview
Go deeper on ChiCTR2300076108.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300076108.